Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy

Purpose: The purpose of this study was to determine the comparative effectiveness of androgen deprivation therapy (ADT) combined with docetaxel (DTX)-based chemotherapy in Korean and Japanese castration-resistant prostate cancer (CRPC) patient cohorts. Materials and Methods: Metastatic CRPC patie...

Full description

Bibliographic Details
Main Authors:	Kyungchan Min, Jae-Wook Chung, Yun-Sok Ha, Jun Nyung Lee, Bum Soo Kim, Hyun Tae Kim, Tae-Hwan Kim, Eun Sang Yoo, Tae Gyun Kwon, Sung Kwang Chung, Masatoshi Tanaka, Shin Egawa, Takahiro Kimura, Seock Hwan Choi
Format:	Article
Language:	English
Published:	Korean Society for Sexual Medicine and Andrology 2020-04-01
Series:	The World Journal of Men's Health
Subjects:	antineoplastic hormonal drugs docetaxel progression-free survival prostate cancer

Similar Items

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
by: Seonggyu Byeon, et al.
Published: (2020-11-01)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
by: Li Q, et al.
Published: (2019-12-01)

Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
by: Whi-An Kwon, et al.
Published: (2019-05-01)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01)

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
by: Sang Eun Yoon, et al.
Published: (2019-05-01)

POSSIBILITIES OF A COMBINATION OF DOCETAXEL WITH ANDROGEN DEPRIVATION IN INITIAL THERAPY OF HORMONESENSITIVE PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
by: Peng-Fei Zhang, et al.
Published: (2021-01-01)

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
by: Xin Hu, et al.
Published: (2019-12-01)

A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer
by: Eric Zhuang, et al.
Published: (2021-11-01)

A randomized study of docetaxel plus cisplatin versus paclitaxel plus cisplatin in previously untreated advanced non-small cell lung cancer
by: Haiyong WANG, et al.
Published: (2008-02-01)

Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer
by: Kai-Fu Yang, et al.
Published: (2015-12-01)

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
by: C Mirjolet, et al.
Published: (2017-08-01)

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
by: Hu L, et al.
Published: (2020-06-01)

Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castration-resistant Prostate Cancer Patients
by: DUAN Liqun, et al.
Published: (2019-09-01)

Weekly low-dose docetaxel is an effective treatment with fewer adverse events for metastatic castration-resistant prostate cancer in Taiwanese patients
by: Cheng-Li Kao, et al.
Published: (2015-12-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer
by: Yuan-Chi Shen, et al.
Published: (2016-09-01)

Docetaxel-related interstitial pneumonitis
by: Wang CJ, et al.
Published: (2015-12-01)

Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort
by: Aurelia H. M. deVries Schultink, et al.
Published: (2019-04-01)

Polyunsaturated fatty acid-based targeted nanotherapeutics to enhance the therapeutic efficacy of docetaxel
by: Thiruganesh Ramasamy, et al.
Published: (2017-01-01)

Advance of second-line chemotherapy in advanced non-small cell lung cancer
by: Li ZHANG
Published: (2008-02-01)

Periungual lesions secondary to chemotherapy with docetaxel
by: Dawid Sigorski, et al.
Published: (2020-02-01)

Complete androgen blockade safely allows for delay of cytotoxic chemotherapy in castration refractory prostate cancer
by: Rafael A. Kaliks, et al.
Published: (2010-06-01)

Docetaxel for High-Grade Mucoepidermoid Carcinoma of the Lung
by: Hui-Ching Wang, et al.
Published: (2015-09-01)

Molecular mechanisms of docetaxel resistance in breast cancer
by: Kastl, Lena
Published: (2007)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
by: Jie Xu, et al.
Published: (2018-10-01)

Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
by: A. V. Rudakova, et al.
Published: (2014-11-01)

Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy
by: A. V. Rudakova, et al.
Published: (2014-11-01)

Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer
by: Zhang X, et al.
Published: (2019-04-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-04-01)

An investigation of the molecular mechanisms of docetaxel resistance in breast cancer cells
by: Sangrithi-Wallace, Jay N.
Published: (2009)

Aqueous extract of Phragmitis rhizoma ameliorates myelotoxicity of docetaxel in vitro and in vivo
by: Jinhee Kim, et al.
Published: (2017-08-01)

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
by: Judith Passildas‐Jahanmohan, et al.
Published: (2021-04-01)

Successful Treatment of MMP-9-Expressing Angiosarcoma with Low-Dose Docetaxel and Bisphosphonate
by: Masaya Ishibashi, et al.
Published: (2012-01-01)

Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report
by: Ryo Fujiwara, et al.
Published: (2015-08-01)

No relation between docetaxel administration route and high‐grade diarrhea incidence
by: Jeroen J. M. A. Hendrikx, et al.
Published: (2020-08-01)

A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
by: A. V. Kondrashina, et al.
Published: (2018-05-01)

Safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy: a phase II, multicenter, single-arm, open-label study
by: B. Ya. Alekseev, et al.
Published: (2018-04-01)

Nanocrystal-Loaded Micelles for the Enhanced In Vivo Circulation of Docetaxel
by: Meng Cheng, et al.
Published: (2021-07-01)

Docetaxel-loaded multilayer nanoparticles with nanodroplets for cancer therapy
by: Oh KS, et al.
Published: (2016-03-01)